A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients

Name: A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients
Published: 2025
License: Public Domain

Novartis Pharmaceuticals · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

african-american breast-cancer older-adults real-world-evidence

breast cancer, ribociclib, cdk4/6 inhibitor, metastatic breast cancer, hr+/her2-, real-world evidence, treatment patterns, dose modification, tolerability, older adults, african american, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients

Related documents